AbbVie bets $10 billion on ImmunoGen to boost its oncology portfolio

30 November 2023
abbvie_big-1

Shares of US antibody-drug conjugate (ADC) specialist ImmunoGen (Nasdaq: IMGN) shot up more that 83% to $29.46 pre-market today, on the news of a definitive agreement to be acquired by pharma major AbbVie (NYSE: ABBV).

The attraction for AbbVie is ImmunoGen’s flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class ADC approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.

The ADC market has attracted huge interest, for example Pfizer’s (NYSE: PFE) $43 billion acquisition of Seagen, as well as dozens of licensing deals. The sector was valued at $4 billion in 2021 and is forecast to rise to $13.13 billion by 2030, delivering a compund annual growth rate over 2021-2030 of 14.12%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology